<DOC>
	<DOCNO>NCT01271322</DOCNO>
	<brief_summary>Prospective , single-center , nonrandomized , explorative imaging study evaluate value PET predictor histopathological response metabolic non-responders Patients resectable AEG ( adenocarcinoma esophagogastric junction ) type I II ( cT3/4 and/or cN+ cM0 ) Metabolic non-responders , show &lt; 35 % decrease SUV ( standardize uptake value ) two week start neoadjuvant chemotherapy eligible study take intensified taxane-based RCT ( radiochemotherapy ) surgery . 18FDG-PET scan perform ( =Baseline ) 14 day standard neoadjuvant therapy well first cycle Taxotere/Cisplatin chemotherapy ( =PET1 ) end intensify radiochemotherapy ( PET2 ) . Tracer uptake assess semiquantitatively use standardize uptake value ( SUV ) . The percentage difference Delta SUV=100 ( SUVBaseline-SUVPET1 ) / SUVBaseline calculate assess early predictor histopathological response . In secondary analysis , association difference SUVPET1 - SUVPET2 histopathological response evaluate .</brief_summary>
	<brief_title>Sequential FDG-PET ( Positron Emission Tomography ) Induction Chemotherapy Locally Advanced Adenocarcinoma Esophagogastric Junction ( AEG )</brief_title>
	<detailed_description>The HICON trial prospective , single-center , nonrandomized , explorative imaging study evaluate value PET ( Positron emission tomography ) predictor histopathological response metabolic non-responders Patients resectable AEG ( adenocarcinoma esophagogastric junction ) type I II , stag cT3/4 and/or cN+ cM0 endoscopic ultrasound , spiral CT MRI FDG-PET eligible . Tumors must potentially R0 resectable must sufficient FDG-baseline uptake . Only metabolic non-responders , show &lt; 35 % decrease SUV ( standardize uptake value ) two week start neoadjuvant chemotherapy eligible study take intensified taxane-based RCT ( chemoradiotherapy ( 45 Gy ) surgery . 18FDG-PET scan perform ( =Baseline ) 14 day standard neoadjuvant therapy well first cycle Taxotere/Cisplatin chemotherapy ( =PET1 ) end intensify radiochemotherapy ( PET2 ) . Tracer uptake assess semiquantitatively use standardize uptake value ( SUV ) . The percentage difference Delta SUV=100 ( SUVBaseline-SUVPET1 ) / SUVBaseline calculate assess early predictor histopathological response . In secondary analysis , association difference SUVPET1 - SUVPET2 histopathological response evaluated..</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Biopsyproven adenocarcinoma distal oesophagus ( AEG type I ) cardia ( AEG type II ) without metastasis local lymph node ( tumor stage cT3/T4 , cNX , cM0 tumornodemetastasis classification ) Staging procedure include endoscopy , endoscopic ultrasound compute tomography ( CT ) chest abdomen . Eligible patient fit platincontaining chemotherapy Tumors must potentially R0 resectable tumor consecutive operation . Tumors must demonstrate minimal amount FDGuptake baseline PETCT , define 18FDGuptake tumor first examination &gt; 1,35 x hepaticSUV + 2 x standarddeviation hepaticSUV , must metabolic nonresponder EOX , define decrease SUVmax &lt; 35 % second PET day 14 chemotherapy . Eastern Cooperative Oncology Group score &gt; 1 Previous secondary malignancy Life expectancy le 3 month Uncontrolled bleed tumor Tumor infiltration airway Pregnancy Uncontrolled diabetes Patients also ineligible undergone previous chemotherapy , radiotherapy , endoscopic laser therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>PET</keyword>
	<keyword>response evaluation</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>radiochemotherapy</keyword>
	<keyword>adenocarcinoma esophagogastric junction</keyword>
	<keyword>esophageal carcinoma</keyword>
	<keyword>evaluation preoperative ( radio ) -chemotherapy patient adenocarcinomas oesophagogastric junction</keyword>
</DOC>